KDC-MN-1324 – Kodiac biolabs

Our opinion on this compoundSingle-lab provenance

43/100

Mechanism premise is genuinely interesting but evidence is trapped in a single Russian research group

Look, Ladasten has an actually interesting mechanism story, and that’s worth acknowledging upfront. Most stimulants and anxiolytics work by pushing neurotransmitters around, releasing dopamine from vesicles or blocking reuptake. Ladasten’s proposed mechanism is different: it appears to upregulate tyrosine hydroxylase and aromatic L-amino acid decarboxylase transcription in mesolimbic dopaminergic neurons, meaning it’s inducing the biosynthetic machinery rather than depleting stores. If that holds under independent scrutiny, it’s a genuinely useful angle for researchers studying dopamine homeostasis and tolerance-free stimulant pharmacology. The dual combination with GABA-A modulation and immunorestorative activity in stress models adds real mechanistic texture to the compound class.

That’s the good news. Here’s the problem: the evidence base for Ladasten is almost entirely Russian-language, produced by the same research-clinical group that developed it, and published in journals that don’t circulate widely in Western pharmacology. Phase 3 data exist for neurasthenia and post-infectious asthenia at 50 to 100 mg daily for 28 days, but neurasthenia as a diagnostic category sits in contested territory between Western and Eastern European clinical frameworks. Theres no FDA or EMA trial record, no independent Western replication, and no multi-lab mechanistic verification. That pattern should be familiar to anyone who has worked with Epitalon or Cerebrolysin: real clinical infrastructure, but closed-loop evidence that’s nearly impossible to evaluate from outside the originating institution.

The actoprotectant compound class is underrepresented in Western literature relative to its apparent practical utility in Soviet-era sports and military research programs. Bromantane, the closely related parent, attracted Western pharmacology attention after the 1996 Atlanta Olympics doping findings, which at least generated some accessible English-language mechanistic work. Ladasten’s longer plasma duration relative to bromantane is reported in Russian monographs but hasn’t been independently confirmed in a Western pharmacokinetic study, which means we’re essentially taking the originating group’s word on the improved profile. The differentiation claim is interesting but unverifiable from the outside.

We think Ladasten is worth monitoring if you’re building a program around dopamine biosynthesis modulation, tolerance mechanisms, or actoprotection biology. The mechanism premise is solid enough to take seriously, and the adverse event profile looks benign in the registered-use dataset. But it cant carry a serious research program on its own at this evidence level. Sourcing is a real practical barrier too: the compound isn’t available through standard Western research suppliers, and quality verification outside of Russian pharmaceutical channels is genuinely difficult. For a bench scientist right now, this is a compound to put on the watch list, not the priority queue.

Novelty: 50
Mechanism promise: 62
In-category differentiation: 40
Evidence quality: 28
Translational signal: 33
Research bench value: 38

Rationale Ladasten scores modestly on novelty and mechanism because the dopamine biosynthesis-induction angle is a real pharmacological differentiator from release-based stimulants, but the evidence base is almost entirely single-consortium Russian-language output with no Western replication, no independent PK confirmation, and clinical trial framing around a contested diagnostic category (neurasthenia), placing it firmly in single-lab-only territory around the Epitalon-to-BPC-157 range.

Adamantane-derived actoprotectant and atypical anxiolytic

An N-substituted adamantyl bromophenylamine related to bromantane with longer plasma duration, registered in the Russian Federation as Ladasten for asthenic conditions.

Abstract

Ladasten (bromantane analog; N-(2-adamantyl)-N-(4-bromophenyl)amine derivative; INN bromantane in some sources but distinguished by the longer-acting Russian preparation; CAS for bromantane parent 40165-90-2) is an adamantane-class atypical psychostimulant and actoprotectant developed at the Russian Academy of Sciences and registered by the Russian Ministry of Health in the early 2000s for the treatment of asthenia and idiopathic chronic fatigue. Ladasten is closely related to bromantane and shares the dual immunomodulatory and dopaminergic profile of that parent compound, but Russian-language pharmacology reports describe a longer plasma half-life and a more pronounced antiasthenic effect at lower mass doses (50 to 100 mg daily versus 100 to 200 mg for bromantane). Mechanism is multifactorial and incompletely characterized in Western pharmacology: principal effects include induction of tyrosine hydroxylase and aromatic L-amino acid decarboxylase transcripts in mesolimbic dopaminergic neurons (driving sustained dopamine biosynthesis rather than release-mediated stimulation), modulation of GABA-A and serotonergic tone, and immunorestorative activity in stress models. The behavioral signature is anxiolysis without sedation combined with restoration of physical and cognitive performance under fatigue conditions, distinguishing the compound from classical psychostimulants and from benzodiazepine anxiolytics. Western clinical trial data are absent. Published Russian Phase 3 data describe efficacy in neurasthenia and post-infectious asthenia at 50 to 100 mg per day for 28 days. The compound is not approved by FDA, EMA, or any regulatory authority outside the Russian Federation and Eastern European member states; the published evidence base is dominated by a single research-clinical group, which is the principal limitation. Adverse event profile is benign at registered doses, with mild gastrointestinal upset and transient activation reported.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1324Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1324

Ladasten

Abstract

Read the full monograph